1 min read

Pegasus Receives FDA Approval for Second Generic Pharmaceutical: Firocoxib Tablets for Dogs

PRN Pharmacal : Updated on June 23, 2026

News & Updates
Pegasus Receives FDA Approval for Second Generic Pharmaceutical: Firocoxib Tablets for Dogs
The U.S. Food and Drug Administration (FDA) has approved Firocoxib Tablets for Dogs. To be marketed under the brand name Sē•Qual™, Firocoxib Chewable Tablets for Dogs joins Firocoxib Tablets for Horses as the second generic nonsteroidal anti-inflammatory drug (NSAID) in the Sē•Qual™ family. Firocoxib Tablets for Dogs is used to control pain and inflammation associated with osteoarthritis, and for the control of postoperative pain and inflammation associated with soft-tissue and orthopedic surgery in dogs. A generic of the pioneer brand known as Previcox® by Boehringer-Ingelheim®, Firocoxib Chewable Tablets for Dogs works by affecting certain enzymes that trigger pain, fever, and inflammation. Firocoxib Tablets for Dogs will be available in 60-count bottles as half-scored tablets in 57mg of firocoxib. Available only by prescription, Firocoxib Chewable Tablets for Dogs is currently in production and will be accessible to veterinarians and their customers by August. The Sē•Qual brand reflects Pegasus Labs’ commitment to quality manufacturing, while acknowledging that the generic products will be the second chapter (or “sequel”) to the pioneer drugs. About Pegasus Pegasus Laboratories was founded in 1986 and acquired by PBI-Gordon Corporation in 1999. A Contract Development and Manufacturing Organization, Pegasus produces animal health products, and distributes products under the PRN® Pharmacal brand name into the veterinary market. Pegasus Laboratories provides full turn-key technical services in a cGMP facility that is DEA-approved.
Previcox® is a registered trademark of Boehringer Ingelheim